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Microtubule-associated protein 2 (MAP2) is a neuronal protein that plays a role in 
maintaining dendritic structure through its interaction with microtubules. In schizophrenia (Sz), a 
number of studies have revealed that MAP2’s typically robust immunoreactivity (IR) is 
significantly reduced across several cortical regions. Previous studies have not explored the 
relationship between MAP2-IR reduction and lower dendritic spine density, which is frequently 
reported in schizophrenia nor has MAP2-IR loss been investigated in the primary auditory cortex 
(Brodmann Area 41), a site of conserved pathology in Sz. Last, the impact of chronic 
antipsychotic exposure is little understood. Using quantitative spinning disk confocal microscopy 
in two cohorts of Sz subjects and matched control subjects (Sz, n=20; C, n=20), we measured 
MAP2-IR as well as dendritic spine density and spine number in deep layer 3 of BA41. Sz 
subjects exhibited a significant reduction in MAP2-IR. The reductions in MAP2-IR were not 
associated with neuron loss, loss of MAP2 protein, clinical confounds, or technical factors; nor 
were MAP2-IR reductions linked with chronic haloperidol exposure in a macaque model. 
Dendritic spine density and number were also reduced in Sz and correlated with MAP2-IR. 
Twelve (60%) Sz subjects exhibited MAP2-IR values lower than the lowest controls; only in this 
group were spine density and number significantly reduced. These findings demonstrate that 
MAP2-IR loss is closely linked to dendritic spine pathology in Sz. Because MAP2 shares 
substantial sequence, regulatory, and functional homology with MAP tau, the wealth of 
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knowledge regarding tau biology and the rapidly expanding field of tau therapeutics provide 
resources for identifying how MAP2 is altered in Sz and possible leads to novel therapeutics. 
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2.0  SCHIZOPHRENIA: EPIDEMIOLOGY AND ETIOPATHOLOGY 
2.1 PREVALENCE AND PRESENTATION 
Schizophrenia (Sz) is a devastating, progressive psychiatric disorder that affects between 
0.5-1% of the global population (Jablensky 2000) . Most individuals present with symptoms 
during late adolescence and early adulthood, generally between the ages of 18 and 30, a period of 
rapid cortical development and social, occupational, and educational transition (Moyer et al 
2015). During this time of developmental sensitivity, stressful life events can produce psychiatric 
pathology in genetically vulnerable individuals. Males typically have an earlier age of onset, a 
higher lifetime risk of developing Sz, and tend to have a poorer prognosis overall. Though, for 
all afflicted, Sz incurs a considerable interpersonal cost in terms of lost educational and 
employment opportunities, difficulties in managing social relationships, and maintaining 
independent self-care. The clinical population experiences a shortening of general life 
expectancy compared to the general population of between two to three decades, partly 
attributable to increased rates of substance abuse and suicide but also due to a greater incidence 
of comorbid cardiovascular disease (Lewis and Sweet 2009, Moyer et al 2015, Salyers and 
Mueser 2001, Tiihonen et al 2009). 
While highly heterogeneous, the disorder is characterized by a pattern of symptomology 
divided into three major domains: positive, negative, and cognitive. Positive symptoms, also 
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referred to as psychotic symptoms, are abnormal functions which distort reality. Hallucinations, 
especially auditory verbal hallucinations, are classically associated with Sz. However, positive 
symptomology extends beyond a distortion in the normal perception of the external world and 
includes a parallel distortion in the production of normal thought, speech, and psychomotor 
activity. This often manifests in delusional thinking, false beliefs, loose associations, over-
inclusiveness, and neologisms (i.e. the creation of new words or expressions). Psychomotor 
impairments are expressed as grossly disorganized behavior and posturing. While positive 
symptoms may be conceived as the addition of abnormal functions, negative symptoms describe 
a loss of normal functions. Negative symptoms include alogia (i.e. poverty in speech 
production), avolition (i.e. a deficit in motivation), and anhedonia (i.e. a deficit in the ability to 
experience pleasure) (Chapman 1966, Lewis and Sweet 2009).  
Cognitive symptoms are deficits in higher executive function including attention, 
working and episodic memory, impulse control, and social engagement. Evidence places the 
cognitive symptomology at the core of the disorder. The degree of cognitive symptomology is 
relatively stable over the course of the disorder and is independent from the severity of positive 
symptoms. Cognitive deficits are present during developmental stages prior to diagnosis and 
become overt during the first clinical presentation. The large majority of Sz patients (i.e. between 
75%-85%) perform 1-3 standard deviations below control subjects on tests of specific 
neuropsychological abilities such as attention, learning, memory, and abstraction. This finding 
holds true both for chronic Sz patients and for neuroleptic naive individuals assessed at their 
first-episode of psychosis. Retrospective studies of Sz patients which compare their academic 
performance to that of their peers prior to disease onset, show that individuals who go on to 
develop Sz are more likely to under-perform academically and are less likely to be in an age-
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appropriate class as a result. The idea that cognitive symptoms are at the core of schizophrenia is 
lent further credence by the fact that cognitive symptomology remains the best predictor of long-
term functional outcome (Lewis and Sweet 2009, Reichenberg and Davidson 2006). Cognitive 
pathology extends into deficits in socio-emotional processing. Deficits in attention, a distinctly 
neurocognitive domain, are strongly associated with the acquisition of social skills; indeed it is 
cognitive symptoms which correlate most strongly with functional impairment (Green 1996).    
2.2 GENETIC AND ENVIRONMENTAL INFLUENCES 
Sz is a highly heritable disorder, and while simple Mendelian genetics do not account for 
the transition to psychosis, recent evidence links a number of genetic loci to the disorder.  
 Genome–Wide Association Studies (GWAS) have identified a number of single 
nucleotide polymorphisms in genetic regions whose activity plays a role in glutamatergic 
circuitry (NRGN), synaptic function (CACNA1C), verbal ability (ZNF804A), neurodevelopment 
(TCF4), and immune response (MHC) (Consortium 2014, Owen et al 2010, Pocklington et al 
2014). This lends support to the validity of the findings in that these systems are linked to the 
phenotypic expression of Sz. However, direct links between alterations to risk genes and the 
development or pathology of Sz have not been identified.  It is important to recognize that, 
individually, identified risk alleles confer little to disease liability. Summing the effect of 
contributions from thousands of common, small effect alleles reveals a robust polygenic 
component to disease heritability. The emerging genetic picture involves the dual contribution 
from many, common small-effect allelic variants and more rare risk variants with much greater 
effect (Owen et al 2010). The interplay between the genetics and pathophysiology of Sz is 
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difficult to disentangle because target genes perform varied cellular functions and interact with a 
multitude of protein partners. As a result of complex heritability, broadly overlapping symptoms, 
and shared genetic risk loci, Sz is often comorbid with other diagnoses including affective, 
addiction, and anxiety disorders.  Specifically, risk loci CACNA1C and ZNF804A achieve 
genome-wide significance in GWAS of Bipolar Disorder (BD). This fact, combined with 
evidence that polygenic scores of risk-alleles common in Sz are found in higher prevalence in 
BD than in controls, suggests a strong genetic overlap between the disorders (Owen et al 2010).  
It is clear that Sz is a complex trait. The polygenic allelic variation which underlies Sz also 
underlies non-clinical endophenotypes present in unaffected first degree relatives, and the 
common allelic variations apparent in Sz are found in individuals without any identifiable 
neurodevelopmental phenotype. The high genetic variability of Sz has led some to postulate that 
Sz is in truth a group of phenotypically related disorders that are etiopathologically distinct 
(Consortium 2014).  
  Data from twin cohorts produce two clear lessons about the heritability of Sz. The first 
is the degree of shared genetics predicts liability to Sz in relatives to those with the disorder; the 
second is that environmental effects play an enormous role in producing clinical pathology 
despite genetic vulnerability. As stated above, the global prevalence of Sz is ~1%; however, the 
incidence rate doubles in 3rd degree relatives, increases to as high as 6% in 2nd degree relatives, 
and increases further to between 6-17% in 1st degree relatives. Dyzogtic twins share an 
incidence rate of ~17% and monozygotic twins share an incidence rate ~50%. Meta-analysis of 
twin studies places the estimate of heritability of liability to Sz at ~81% (Lewis and Lieberman 
2000, Sullivan et al 2003). Given that monozygotic twins are genetically identical, the fact they 
do not share absolute concordance for Sz reveals unique environmental effects play a significant 
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role in developing clinical pathology even when environmental influences greatly overlap (e.g. 
shared gestation, common upbringing). A number of environmental risk factors, clustered during 
early development, have been found to contribute to the prevalence of Sz including prenatal 
maternal infection, prenatal maternal stress, fetal hypoxia, and obstetric complications (Ellman 
and Cannon 2006). Other environmental risk factors have their effect during later maturational 
stages, including early childhood social isolation, heavy adolescent cannabis exposure, 
emigration to a region in which one is an ethnic or racial minority, and urban residency (Lewis 
and Lieberman 2000). 
2.3 AUDITORY CORTEX AS MODEL CORTICAL SYSTEM 
Many studies of the cortical pathology associated with Sz focus on areas responsible for 
executive function and memory. However, the auditory cortex is an especially important site for 
understanding the pathophysiology of Sz. While the pathogenesis of the disorder involves 
genetic factors and developmentally early insults, the first episode of psychosis rarely occurs 
before the onset of puberty. The maturation of the auditory cortex follows a parallel timeline and 
is not complete until an individual’s third decade. This protracted maturational process may 
leave this region particularly vulnerable to the effect of environmental stressors, an idea which is 
supported by structural, cellular, and molecular alterations specific to this area in disease (Moyer 
et al 2015). As is discussed in further detail below, abnormalities in the auditory domain are 
tightly linked to schizophrenia pathology with serious implications for the individual’s prognosis 
and abilities. For additional information on the role of the auditory cortex in disease, see section 
3.1. The auditory cortex has added value as a model system in its conservation through species. 
 7 
Prefrontal regions are uniquely developed in primate species, especially humans, which makes 
modelling the relationships between structural and molecular changes and alterations to behavior 
in animal models difficult to interpret.      
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3.0  LOSS OF MICROTUBULE ASSOCIATED PROTEIN 2 IMMUNOREACTIVITY 
LINKED TO DENDRITIC SPINE LOSS IN SCHIZOPHRENIA 
3.1 INTRODUCTION 
Individuals with schizophrenia (Sz) present with a number of functional deficits in the auditory 
domain. Patients exhibit impaired performance on pure tone discrimination tasks, an inability 
which does not depend on attention and thus implicates the auditory cortex itself (2000, Leitman 
et al 2010, Rabinowicz et al 2000). This functional deficit has consequences for social cognition 
in individuals with the disorder in that it makes prosody detection more difficult (Javitt 2009, 
Leitman et al 2006). In electrophysiological studies, Sz subjects display reduced amplitude on 
mismatch negativity(Javitt et al 2000, Naatanen and Kahkonen 2009, Umbricht et al 2003, 
Umbricht and Krljes 2005) (MMN), an event-related potential generated in the primary auditory 
cortex in response to stimuli deviant from preceding stimuli with respect to a particular feature 
(e.g. pitch, amplitude, duration)(Javitt et al 1994). Performance on tone discrimination tasks and 
MMN amplitude are correlated, and impairments on both are linked to severity of positive and 
negative symptoms (Hermens et al 2010, Javitt et al 2000, Rabinowicz et al 2000).  
These functional and electrophysiological deficits are paralleled at the cortical level by 
progressive gray matter volume reduction in the superior temporal gyrus (STG) in Sz subjects 
and first-degree relatives at high-risk (McCarley et al 1999, Rajarethinam et al 2004) and 
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specifically in Heschl’s gyrus which contains the primary auditory cortex (Hirayasu et al 2000, 
Kasai et al 2003, Rajarethinam et al 2004, Salisbury et al 2007, Takahashi et al 2009) (Brodmann 
area 41; BA41). Reductions in gray matter are found at (Rajarethinam et al 2004, Takahashi et al 
2009), or prior to transition to, (Hirayasu et al 2000, Kasai et al 2003, Salisbury et al 2007) the 
first psychotic episode indicating initial gray matter loss cannot be attributed to the effects of 
treatment or illness duration. STG gray matter loss is selective for individuals with Sz in 
comparison to those diagnosed with bipolar disorder (Hirayasu et al 2000, Kasai et al 2003, 
Salisbury et al 2007).  
Gray matter volume loss in the auditory cortex in Sz is not explained by underlying 
reductions in layer 3 pyramidal neuron number(Dorph-Petersen et al 2009), and more likely 
represents reductions in pyramidal neuron somal size and excitatory connections in this cortical 
region (Sweet et al 2004, Sweet et al 2009). We previously described a decrease in the density of 
spinophillin-immunoreactive puncta in deep layer 3 of the primary auditory cortex in Sz, 
representing reductions in pyramidal neuron spine density paralleling findings of a loss of spines 
per length of dendrite described in other cortical regions (Garey et al 1998, Glantz and Lewis 
2000, Rosoklija et al 2000). Sz is also characterized by a reduction in the extent and complexity 
of the dendritic arbor in hippocampus and cingulate and frontal cortices (Black et al 2004, 
Broadbelt et al 2002, Glantz and Lewis 2000, Kalus et al 2000). However, the molecular 
mechanisms that contribute to these concurrent reductions in dendrites and spines in disease are 
currently unknown.  
Microtubule associated protein 2 (MAP2) stands at the intersection of these phenomena. 
MAP2 is the most prevalent isoform of the dendritic MAPs, a family of cytoarchitectural 
proteins that includes the axonal homolog MAP tau (Dehmelt and Halpain 2005, Sanchez et al 
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2000). MAP2 is an important regulator of neuritic development and maintenance that acts by 
binding and nucleating the primary structural component of the dendritic cytoskeleton, 
microtubule (MT) monomers and subsequently stabilizing and spacing mature MT bundles in the 
dendrite.(Belanger et al 2002, Dehmelt and Halpain 2005, Farah and Leclerc 2008, Sanchez et al 
2000, Teng et al 2001). MAP2 plays a similar role in supporting the actin cytoskeleton in spines, 
binding and nucleating filamentous actin (f-actin) to regulate spine morphology.(Selden and 
Pollard 1983)  MAP2 is regulated by development and experience-dependent plasticity, with 
these processes tightly controlling MAP2 function by phosphorylation across its functional 
domains (Sanchez et al 2000). MAP2 immunoreactivity (MAP2-IR) is markedly reduced in a 
number of different cortical regions associated with Sz pathology including those regions where 
reduction of the dendritic arbor has been described (Arnold et al 1991, Jones et al 2002, Rioux et 
al 2004, Rosoklija et al 2005, Somenarain and Jones 2010) (e.g. cingulate and frontal cortices, 
hippocampal formation). However, MAP2 mRNA expression levels are unchanged in the 
disorder suggesting that Sz pathology impacts MAP2 protein and not its transcript (Law et al 
2004).  
In the present study, we investigated whether MAP2-IR is diminished in deep layer 3 of 
the primary auditory cortex of Sz subjects and its potential association with spine reduction, 
which we have previously observed in this layer (Sweet et al 2009). To address this question, we 
used multi-label quantitative fluorescence microscopy to measure the intensity of MAP2-IR, 
spine density, and spine number in 20 subjects with Sz and matched controls. We found that 
MAP2-IR was significantly decreased in individuals with Sz, with a subset of 60% of Sz subjects 
that exhibited MAP2-IR levels below the lowest level observed in controls. MAP2-IR was 
significantly associated with spine density and spine number, with reductions in spine density 
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and number restricted to the 60% of subjects with Sz with MAP2-IR below normal levels. These 
findings suggest that MAP2 is functionally compromised by disease pathology with implications 
for dendritic arbor and dendritic spine structural integrity. 
3.2 MATERIALS AND METHODS 
3.2.1 Human Subjects  
For this study, we used tissue from two cohorts (Table 1) comprised of subjects 
diagnosed with schizophrenia or schizoaffective disorder (together referred to as Sz) and controls 
matched on the basis of sex, and as closely as possible for age, post-mortem interval (PMI), and 
handedness. Brain tissue was obtained during autopsies conducted at the Allegheny County 
Office of the Medical Examiner, after receiving consent from next-of-kin using a mechanism 
approved by the University of Pittsburgh Institutional Review Board and Committee for 
Oversight of Research Involving the Dead. An independent committee of experienced clinicians 
made consensus DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th ed.) 
diagnoses for each subject, using information obtained from clinical records and structured 
interviews with surviving relatives as previously described.(Glantz and Lewis 2000, Sweet et al 
2009) 
 
 Cohort 1 Cohort 2 Total 
 Control Sz Control Sz Control Sz 
n 12 12 8 8 20 20 
Mean Age (SD) 45.2(12.9) 47.3(13.4) 46.4(14.0) 46.5(12.4) 45.8(13.0) 46.9(13.4) 
     Range 19-65 27-71 24-62 25-62 19-65 25-71 
Sex (F/M) 3/9 3/9 4/4 4/4 7/13 7/13 
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Handedness 
(R/L/A/U/) 
11/1/0/0 6/2/1/3 8/0/0/0 5/3/0/0 19/1/0/0 11/5/1/3 
PMI (SD) 18.1(6.5) 17.9(8.8) 13.7(6.5) 15.6(6.8) 16.4(6.7) 17.0(7.9) 
Storage Time , 
Months (SD) 
155.0(27.2) 145.5(29.8) 97.1(22.4) 92.8(14.0) 131.8(38.2) 124.4(35.9) 
Illness 
Duration, 
Years (SD) 
 22.1(14.7)  22(13.3)  22.1(13.8) 
    Range  3-50  4-41  3-50 
Age at Onset 
(SD) 
 25.2(7.7)  24.5(9.6)  24.9(8.3) 
Suicide, n(%)  2(16.7%)  2(25.0%)  4(20.0%) 
Schizoaffective, 
n (%) 
 4(33.3%)  2(25.0%)  6(30.0%) 
Alcohol/ 
Substance 
Abuse ATOD 
 5(41.7%)  0(0%)  5(25.0%) 
Anticonvulsant 
ATOD, n(%) 
 5(62.5%)  1(12.5%)  6(30.0%) 
Antidepressant 
ATOD, n(%) 
 3(37.5%)  5(62.5%)  8(40.0%) 
Antipsychotic 
ATOD, n(%) 
 11(91.7%)  6(75.0%)  17(85.0%) 
Benzodiazepine 
ATOD, n(%) 
 1(8.3%)  3(37.5%)  4(20.0%) 
History of 
Cannabis Use, 
n(%) 
 5(41.7%)  2(25.0%)  7(35.0%) 
Tobacco 
ATOD, n(%) 
4(33.3%) 8(66.7%) 3(37.5%) 6(75.0%) 7(35.0%) 14(70.0%) 
Table 1. Subject Characteristics. Each Sz subject in cohorts 1 and 2 was previously 
matched to a normal control subject based on sex, and as closely as possible for age and 
postmortem interval. There were no diagnostic group differences in age [t(38) = -
0.333, p = 0.741] or postmortem interval [t(38) = -0.272, p = 0.787]. The distribution of 
handedness between diagnostic groups reached trend level (χ2 = 8.800, p = 0.066). Mean 
tissue storage time did not differ between diagnostic groups [cohort 1: t(22) = 0.817,p = 
0.423; cohort 2: t(14) = 0.461, p = 0.652].  
F, female; M, male; R, right-handed; L, left-handed; A, ambidextrous; U, unknown; PMI, 
postmortem interval; ATOD, at time of death. 
 
3.2.2  Antipsychotic-exposed Monkey Cohort.  
We also used a previously described monkey (Macaca fascicularis) cohort comprised of four 
animals chronically administered the antipsychotic haloperidol decanoate and age, sex, and 
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weight matched control animals (Figure 1 top panels) (Akil et al 1999, Moyer et al 2012, Moyer 
et al 2013, Sweet et al 2009). Over a period of 9-12 months, macaques were intramuscularly 
administered the antipsychotic haloperidol decanoate every four weeks at a dose [mean (standard 
deviation)] of 16 (2.1) mg/kg which maintained trough serum levels at 4.3 (1.1) ng/ml. Similar 
concentrations have been associated with a therapeutic response in humans, (Volavka et al 1992) 
and resulted in extrapyramidal symptoms, which were effectively controlled in all treated 
animals with benztropine mesylate.  
At the end of haloperidol exposure, all animals were euthanized by pentobarbital 
overdose; brains were removed and immersed in 4% paraformaldehyde following a 45 minute 
PMI. Primary auditory cortex was identified in sections from the STG using previously described 
cytoarchitectonic and immunohistochemical features (Sweet et al 2004). All protocols were 
approved by the University of Pittsburgh’s Institutional Animal Care and Use Committee.  
3.2.3 Human Tissue Processing 
Brains from individuals in cohorts 1 and 2 were bisected and the left hemisphere was cut into 1-2 
cm thick coronal blocks, which were then immersed in 4% paraformaldehyde in phosphate 
buffer for 48 hours, equilibrated in a series of graded sucrose solutions, and stored at -30˚C in an 
antifreeze solution.  
The left superior temporal gyrus (STG) of each subject was dissected from fixed coronal 
blocks; reassembled in their in vivo orientation, and cut into 3mm thick slabs as previously 
described (Sweet et al 2005). Every other slab was selected, sectioned exhaustively, and adjacent 
sections stained for parvalbumin (PV), acetylcholinesterase (AChE), and Nissl substance for 
determination of the boundaries of the primary auditory cortex (Sweet et al 2005). For each 
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human and monkey subject, the borders of layers 2/3 and 3/4 were identified on the mapping 
sections to determine the total layer 3 area for each subject. A contour outline of the deepest one 
third of layer 3 was drawn in Stereo Investigator (Figure 1, MicroBrightField Inc., Colchester, 
Vermont). These contours were then aligned to the tissue sections used in the current study using 
pial surface fiduciaries. 
For cohort 1, the primary auditory cortex was dissected from the unused slabs, and 
further subdivided into 3 mm wide blocks which were sectioned at 50 μm in an orientation 
perpendicular to the pial surface, and stored in antifreeze solution at -30˚C until selected for use 
in this study as described previously (Dorph-Petersen et al 2009, Moyer et al 2012, Moyer et al 
2013). For cohort 2, 60 µm sections adjacent to the mapping sections were sampled systematic 
uniform random for assay (Figure 1).   
 
 
Figure 1. Sampling of primary auditory cortex deep layer 3.  
(Top) Illustration of delineation of primary auditory cortex deep layer 3 on sections 
containing auditory cortex for human and antipsychotic exposed macaque cohorts. For 
each human and monkey subject, the borders of layers 2/3 and 3/4 were identified on 
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adjacent Nissl-stained sections to determine the total layer 3 area for each subject. A 
contour outline (shown in white) of the deepest one third of layer 3 was drawn in Stereo 
Investigator (MicroBrightField Inc., Colchester, Vermont).  (Bottom) A sampling grid 
was created in Stereo Investigator to generate sampling sites for both human and 
nonhuman primate subjects. The grid was then randomly rotated, and a sampling site 
(shown as counting frames) was marked at every intersection between the grid and the 
deep layer 3 contour.  At each sampling site, a 12.5-μm thick stack of 50 image planes, 
each separated by 0.25 μm, was collected using spinning disk confocal microscopy. 
 
3.2.4 Immunohistochemistry 
A single tissue section per subject was included in each run along with its matched pair for a 
total of 3-4 sections per subject from cohort 1 and 3 sections per subject from cohort 2. In order 
to visualize dendritic spines, we used two markers in combination: a polyclonal antibody 
directed against spinophilin and raised in rabbit (Millipore AB5669, Billerica, MA) at a dilution 
of 1:1500. The second was the f-actin binding mushroom toxin phalloidin (Invitrogen A12380, 
Carlsbad, CA) conjugated to Alexa Fluor® 568. Spinophilin is highly enriched in spine 
heads.(Allen et al 1997, Muly et al 2004)  Phalloidin binds f-actin which is also highly enriched 
in dendritic spines (Capani et al 2001). These two labels show clear co-localization in structures 
resembling dendritic spines in human postmortem brain tissue (Figure 2) MAP2 was detected 
through the use of mouse monoclonal IgG antibody SMI-52 (Covance SMI-52R, Princeton, NJ) 
at a dilution of 1:500. SMI-52 has been shown to react with mammalian MAP2 both in culture 
and in fixed sections, robustly labeling the soma and dendritic arbor of neurons in human tissue 
(Anderson et al 1996). In immunoblot experiments, SMI-52 recognizes all isoforms of MAP2 
(MAP2A, MAP2B, MAP2C) (Kaufmann et al 1997). Free-floating sections were pre-treated 
with 1%NaBH4 to reduce auto-fluorescence and 0.3% Triton X in order to permeabilize the 
sections before being incubated for two hours at room temperature in blocking buffer comprised 
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of 20% normal human serum, 20% normal goat serum, 1% bovine serum albumin, 0.1% Lysine, 
0.1% Glycine, and phosphate buffered saline (PBS). Following blocking, tissue was immediately 
placed in primary antibody buffer (5% normal human serum, 5% normal goat serum, 1% bovine 
serum albumin, 0.1% Lysine, 0.1% Glycine, PBS, and antibodies) overnight at 4˚C. Sections 
were rinsed in PBS then incubated in the same buffer, containing biotinylated goat anti-mouse 
(1:250; Invitrogen BA-9200), Alexa Fluor® 488 goat anti-rabbit (1:500; Invitrogen A11034), 
and Phalloidin- Alexa Fluor® 568 (3:200) at 4˚C for 24 hours. Tissue was again rinsed then 
incubated overnight in a 1:500 dilution of streptavidin Alexa Fluor® 647 (Invitrogen, S32357) at 
4˚C. The tissue sections were subsequently mounted on gel-coated slides, rehydrated to 
ameliorate the effects of z-axis tissue shrinkage, and coverslipped using Vectashield hard-set H-
1400 mounting medium (Vector Laboratories, Burlingame, CA). Sections from the 
antipsychotic- and control monkeys were processed together within immunohistochemistry runs 
using identical procedures.   
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Figure 2. Phalloidin labeled and spinophilin-immunoreactive puncta in deep layer 3.  
(Top) Phalloidin labeled puncta (red) and spinophilin-IR puncta (green) co-localize 
throughout deep layer 3 of BA41 and are often organized along MAP2-IR processes 
(blue) suggesting spine structures along dendrites. Images below are a magnification of 
the inset in the top panel more closely revealing the relationship between phalloidin-
labeled (a) and spinophilin-IR objects (b), and their co-localization in putative spine 
structures (c). Scale bar=5 µm. 
3.2.5 Image Collection 
Matched pairs from each cohort were imaged during the same session by an experimenter (JTN) blinded 
to diagnostic or antipsychotic exposure group All images were taken using a 1.42 numerical aperture 
(NA) 60X oil supercorrected objective mounted on an Olympus BX51Wl upright microscope (Olympus, 
Center Valley, PA) equipped with an Olympus DSU spinning disk, Hamamatsu Orca R2 camera 
(Hamamatsu, Bridgewater, NJ), MBF CX9000 front mounted digital camera (MicroBrightField Inc., 
Natick, MA), BioPrecision2 XYZ motorized stage with linear XYZ encoders (Ludl Electronic Products 
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Ltd., Hawthorne, NY), excitation and emission filter wheels (Ludl Electronic Products Ltd., Hawthorne, 
NY), Sedat Quad 89000 filter set (Chroma Technology Corp., Bellows Falls, VT), and a Lumen 220 
metal halide lamp (Prior Scientific, Rockland, MA).  The process of image collection was accomplished 
using Slidebook software version 5.027 (Intelligent Imaging Innovations, Denver, CO) and Stereo 
Investigator version 8 (MicroBrightField Inc., Natick, MA). 
3.2.6 Image Processing 
Images were processed using Slidebook software version 5.027 with keystrokes automated by 
Automation Anywhere software (Automation Anywhere, Inc. San Jose, CA). Camera 
background was subtracted from channels 488 and 568 prior to processing.  
Single plane MAP2 images were masked using a threshold segmentation defined by the 
Ridler Calvard (RC) derived value in Slidebook. Underlying gray level values were extracted 
from the mask objects.  
 
Image stacks were deconvolved using the AutoQuant adaptive blind deconvolution 
algorithm (MediaCybernetics, Rockville, MD). After deconvolution, edges were sharpened by 
taking the difference between images convolved at two standard deviations of the Gaussian 
distribution (σ1=0.7; σ2=2.0) as previously described, (Kirkwood et al 2013) then subjected to 
iterative intensity/morphological segmentation (Fish et al 2008). Spinophilin-IR and phalloidin 
puncta with intensity measures above the RC defined minimum threshold derived value in 
Slidebook were selected and contiguous pixels were defined as a ‘mask object.’ Spinophilin-IR 
and phalloidin mask objects with volumes between 0.1 and 0.8 µm3 and 0.04 and 1.5 µm3, 
respectively, were selected at each iteration. Due to lower spinophilin-IR intensity in cohort 2, it 
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was necessary to begin with a minimum threshold value at 1/3 the RC defined value. At each of 
100 iterations, the threshold intensity was increased and the mask objects combined with those of 
the prior iteration. 
 
3.2.7 Calculation of Spine Density and Number 
While both spinophilin-IR and phalloidin binding are strongly localized to spines, each has some 
off target label (Capani et al 2001, Muly et al 2004) Therefore, identification of putative 
dendritic spines required co-localization of spinophilin-IR and phalloidin label (Figure 2), 
operationalized as phalloidin mask objects that overlapped (≥ 1 voxel) with a spinophilin-IR 
mask object Spine density (Nv) and number (N) in cohort 1 was calculated as previously 
described with minor modification: (Moyer et al 2012, Moyer et al 2013)  
 
 
Where a  is the area of the counting frames,  is the count of dendritic spines within 
the ith block,   is the count of the associated points hitting the region of interest in the ith block, 
h= disector height, BA  is the cryostat block advance (50 μm for cohort 1 and 60 μm for cohort 2, 
  is the block-and-number-weighted mean section thickness calculated using this formula: 
(2) 
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where  is the local section thickness measured centrally in the  jth sampling frame and 
 is the corresponding count of dendritic spines in the jth frame.  is the block weight—i.e. 
either 1 or 1/3. The number of spines was estimated as the product of previously determined 
deep layer 3 volumes in these subjects (Dorph-Petersen et al 2009, Moyer et al 2012, Moyer et al 
2013) and the calculated in the above equation, represented here: 
(3) 
 
Because for cohort 2, sections adjacent to the mapping sections were sampled, calculation 
of   and   were as above but omitting the block weighting (Dorph-Petersen and Lewis 2011).   
 
Phalloidin mask objects overlapping spinophilin mask objects were counted 
automatically by determining whether the centroid of each automatically detected object was 
inside the disector. This corresponds to the so-called “associated point rule” (Baddeley 2005), which is 
an unbiased alternative to the unbiased counting frame (Gundersen 1977).  Guard zones of 10 
pixels were applied around all edges in the X and Y dimensions of each stack, and a guard zone 
of 4 Z planes was provided starting at the top of the tissue below the coverglass. The resulting 
disectors were 492 x 492 pixels in X and Y dimensions, and 24 Z planes (cohort 1) or 4 Z planes 
(cohort 2). These Z ranges were selected based on evidence from calibration plots that puncta 
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counts and intensities were uniform across these Z axis depths.  It should be noted that the 
relatively low disector height (1.0 µm in Cohort 2) could be implemented robustly because we 
used confocal microscopy allowing for a high number of thin focal planes, because of our use of 
deconvolution with full thickness reconstructions and determination of centroids; and because 
we performed a careful analysis of the distribution of the puncta along the Z axis. We determined 
the position of the disector and corresponding guard zones post hoc ensuring that puncta were 
only sampled in the zone with uniform bouton counts. Such sampling was also possible due to 
the high number of automatically detected puncta per subject. Thus, while a disector height of 
only 1.0 µm should be avoided in a standard brightfield microscopy study with manual counts, 
we were able to robustly implement such a disector in the current study. 
 
3.2.8 Statistical Models 
3.2.8.1 Human Tissue Study 
For each subject in the human tissue study, the intensity of MAP2-IR was first log transformed 
to more normally distribute MAP2-IR data. To assess the diagnostic effect in log MAP2-IR, 
spine density, spine number and deep layer 3 volume, two analysis of covariance (ANCOVA) 
models were used. Because we pair subjects within each cohort on age, sex, and postmortem 
interval, the primary model included diagnosis, cohort (which in this case includes effects of 
assay run and imaging run because the cohorts were studied sequentially), pair nested within 
cohort as blocking factors and tissue storage time (which is not a pairing variable, but may affect 
assay fidelity) as a covariate. To then assess the robustness of results, a secondary model was 
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used with diagnosis, cohort, and tissue storage time as covariates, and in place of subject 
pairings, we instead enter as covariates the pairing variables: age, sex, and postmortem interval. 
        In order to examine the confound effect of each of the following factors: sex (F/M), 
manner of death (suicide), diagnostic variation (schizoaffective disorder (Y/N), age of onset, 
duration of disease)), antipsychotic use (Y/N), anticonvulsant use (Y/N), benzodiazepine use 
(Y/N), non-diagnosis related drug treatment (Y/N), and substance abuse/dependence at time of 
death [alcohol (Y/N), tobacco (Y/N), cannabis history (Y/N), non-specified (Y/N)], the pairwise 
percent difference in each of the four variables was analyzed. If the confound variable was 
dichotomous, a two sample t test was used. If the confound variable was continuous, a simple 
linear regression analysis was used. The percent difference in log MAP2-IR within a pair is 
calculated as: 
. 
The pairwise percent differences for other variables were calculated similarly.       
         The relationship between log MAP2-IR and spine density was determined by two 
methods: Pearson’s correlation coefficient and alternatively optimized Kendall’s tau. In order to 
examine the relationship between log MAP2-IR and spine density, both variables were 
dichotomized by choosing cutoff points. A 2 by 2 contingency table was calculated for each 
chosen set of cutoff points. Kendall’s tau was used as the measure of association of the 
contingency table. An optimizing search was used to find the cutoff points for each of 
log(MAP2-IR)  and spine density so that Kendall’s tau was maximized. The asymptotic p-value 
was obtained for the Kendall’s tau to test if it is different from 0.   
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Diagnostic effect in spine density and spine numbers were examined within of the MAP2 
Low and MAP2 Normal subgroups using the same primary and secondary models used on the 
entire 20 pairs of subjects.  
        The analyses for diagnosis effect and confound effect were implemented in SAS 
PROC GLM with alpha 0.05; Kendall’s tau was obtained in SAS PROC FREQ, and the Pearson 
correlation coefficient was obtained in SAS PROC CORR.  
3.2.8.2 Monkey Tissue Study   
For each observation in the monkey tissue study, log MAP2-IR was taken before analysis so that 
MAP2 intensity was more normally distributed. Haloperidol treatment effect was examined with 
two mixed effect models: a primary model with treatment, assay and pair as fixed effect and 
monkey as a normal random effect to account for the repeated measures within one monkey; the 
secondary model was the same as the primary model except that pair was not included in the 
model. The analyses for the monkey tissue study were implemented in SAS PROC MIXED with 
alpha=0.05. 
 
3.3 RESULTS 
3.3.1 MAP2 Immunoreactivity  
MAP2-IR was significantly reduced in Sz subjects compared to their matched control pairs 
(Figure 3) [primary model: F(1,18)=18.32; p=0.001 and secondary model: F(1,33)=13.88; 
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p=0.001]. There was a 70.0% reduction in log MAP2-IR in Sz subjects relative to controls based 
on the primary model. The mean log MAP2-IR (SE) for control and Sz subjects was 3.068 
(0.085) for controls and 2.545 (0.092) for Sz subjects.  
 
Figure 3. MAP2-IR is significantly reduced in Sz primary auditory cortex. 
 (A) MAP2-IR in subject pairs from cohort 1 and cohort 2. The unity line represents 
schizophrenia=control values; points beneath the line represent pairs in which 
schizophrenia<control; points above the line represent schizophrenia>control. The plus 
indicates the group mean. (B) MAP2-IR for control and schizophrenia subjects in cohort 
1 and cohort 2. Bars represent mean IR for each group. (C-D) Representative 
micrographs of MAP2-IR taken from a control subject (left) and schizophrenia subject 
(right); scale bar= 10 µm. (cohort 1, pair 8, filled circle in A). 
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3.3.2 Primary Auditory Cortex Deep Layer 3 Neuron Number in Cohort 1 Subjects 
We previously reported that pyramidal neuron number did not differ between control 
subjects and schizophrenia subjects in individuals from cohort 1 (Dorph-Petersen et al 2009). 
Mean layer 3 pyramidal neuron number for control subjects was 3.38 × 106 and 4.11× 106 for 
schizophrenia subjects, a non-significant difference (F1,10=1.25; p=0.29) The relationship 
between MAP2-IR and pyramidal neuron number is show in Figure 4). This finding confirms 
that MAP2-IR loss is not a result of pyramidal neuron loss.  
 
 
Figure 4. No loss of pyramidal neuron number in primary auditory cortex. 
MAP2-IR plotted as a function of deep layer pyramidal neuron number in primary 
auditory cortex in control subjects (open circles) and schizophrenia subjects (filled 
circles) from cohort 1. For all subjects, r2=0.013; the corresponding values for control, 
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r2=0.0828 and schizophrenia subjects, r2=0.0047. None of the correlations were 
significant. 
 
3.3.3 MAP2 Peptide Amount in Primary Auditory Cortex Deep Layer 3 
MAP2-IR loss could reflect a loss of protein, or a reduction in the ability to bind to its 
epitope.  To determine if MAP2-IR loss is driven by a loss of protein, total protein was extracted 
from gray matter homogenates obtained from Heschl’s gyrus containing the primary auditory 
cortex as previously described (Deo et al 2012). Five MAP2 peptides representing sequences 
along the length of MAP2 protein (Figure 5, Top) were quantified using liquid chromatography-
mass spectrometry with selected reaction monitoring and quantification via a stable isotope 
labeled mouse brain standard as previously described (MacDonald et al 2012). MAP2 peptides 
were quantified in 5 pairs of subjects from the present study in whom the schizophrenia (Sz) 
subject exhibited MAP2-IR values below the lowest control value observed in the entire cohort, 
deemed MAP2-IR Low We found no significant differences in MAP2 peptide levels, despite 
substantial reductions in MAP2-IR in these same subject pairs (Figure 5, Bottom). 
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Figure 5. MAP2 peptide levels are unchanged in MAP2-IR Low Sz subjects. 
 (Top) Schematic of MAP2 protein isoforms. Dark green shows amino acids included in 
isoform MAP2C, whereas MAP2A and MAP2B also include the projection domain 
shown in blue. The locations of other functional domains along the length of MAP2 
(numbering indicates amino acids) are as indicated. Dashed gray lines indicate the 
potential regions within MAP2 to which antibody used in this study (SMI-52, Covance) 
binds. The peptide sequences used for subsequent quantification are shown in their 
respective locations within the MAP2 protein.  (Bottom) Mean ratios of MAP2 peptides 
in five MAP2-IR Low pairs (control, C; schizophrenia, Sz). Mean MAP2-IR for the same 
5 pairs is shown in last panel. **, p<0.01. Error bars are SEM. 
3.3.4 Influence of Post-Mortem Interval on MAP2 Immunoreactivity 
We found no significant effect of post-mortem interval (PMI) in log MAP2-IR based on 
our secondary model in which the term pair is replaced by age, PMI, and sex (F(1,33)=0.06, 
p=0.81; Figure 6).  
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Figure 6. MAP2-IR is unaffected by PMI. 
We found no significant effect of PMI on MAP2-IR. MAP2-IR is shown for each pair in 
order (from left to right) of ascending PMI of the Sz subjects. Control subjects open 
circles; schizophrenia subjects, filled circles.  
3.3.5 Spine Density and Number 
Mean spine density was significantly reduced in Sz subjects compared to matched controls 
[Figure 7A; primary model: F(1,18)=6.17; p=0.023 and secondary model: F(1,33)=8.83; 
p=0.005]. Mean spine density for control subjects [0.0333 µm -3 (0.0018)] and Sz subjects 
[0.0269 µm3 (0.0020)] revealed a 19.22% reduction in spine density.  
The reduction in spine density in Sz subjects was paralleled by an accompanying 
reduction in mean spine number [Figure 7B; primary F(1,18)= 4.13, p=0.057 and secondary 
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F(1,33)=4.46, p=0.042]. The mean spine number (reported in billions) for control and Sz 
subjects were 1.30(0.083) and 1.06(0.009) respectively; a 18.79% reduction in spine number 
across diagnosis. In the secondary model, the effect of cohort was significant [F(1,33)= 6.33, 
p=0.017] but the diagnosis by cohort interaction was not significant. 
 
Figure 7. Spine number/density reduced in Sz primary auditory cortex.  
(A) (Top) Mean spine density in deep layer 3 of primary auditory cortex in pairs from 
cohort 1 and 2. The unity line represents schizophrenia=control values; points beneath the 
line represent pairs in which schizophrenia<control; points above the line represent 
schizophrenia>control. The plus indicates the value of the group mean. (Bottom) Mean 
spine density for control (C) and schizophrenia (Sz) subjects in cohort 1 and cohort 2. 
Error bars are ± SEM. (B) (Top) Spine number in deep layer 3 of primary auditory cortex 
in subject pairs. The unity line and plus symbol represent the same relationships as 
described above. (Bottom) Mean spine number for control (C) and schizophrenia (Sz) 
subjects. Error bars are ± SEM. 
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3.3.6 Association with Clinical Factors 
We examined the effect of a number of clinical factors (e.g. sex, manner of death, diagnostic 
variation, drug exposure, and substance abuse/dependence at time of death) on pairwise percent 
difference in MAP2-IR, spine density, and spine number. No significant associations were 
detected.  
3.3.7 Correlation between MAP2-Immunoreactivity and Dendritic Spine Density and 
Number 
There was a significant linear correlation between MAP2-IR and spine density (r2=0.433, 
p=0.005) but not between MAP2-IR and spine number (r2=0.162, p=0.32). However, the 
optimized Kendall’s tau approach indicated that MAP2-IR and spine density were significantly 
related to each other based on the highest Kendall’s tau obtained (τ=0.562, z=3.08, p=0.002), as 
were MAP2-IR and spine number (τ=0.5295, Z=4.48, p<0.001). 
Twelve Sz subjects (60%) exhibited MAP2-IR values below the lowest control value, 
deemed MAP2-IR Low. MAP2-IR Low subjects had significant reductions, relative to their 
matched controls, in spine density [Figure 8; primary: F(1,10)=15.970, p=0.003 and secondary: 
F(1,17)=16.9, p=0.001] and spine number [Figure 8; primary: F(1,10)=12.06, p=0.006 and 
secondary: F(1,17)=12.01,p=0.003]. MAP2-IR Normal Sz subjects did not differ from their 
matched controls in either spine density [Figure 8; primary: F(1,6)=0.040, p=0.851 and 
secondary: F(1,9)=0.060, p=0.817] or spine number [Figure 8; primary: F(1,6)=0.12,p=0.74 and 
secondary: F(1,9)=0.15,p=0.708].  
 
 31 
 
Figure 8. Relationship of MAP2-IR to dendritic spine number/ density. 
(A) Mean spine density plotted as a function of MAP2-IR for control subjects (open) and 
schizophrenia subjects (crossed) in cohort 1 (unfilled) and cohort 2 (filled).  (B) Spine 
number as a function of MAP2-IR for control subjects (open symbols) and schizophrenia 
subjects (crossed symbols) in cohort 1 (unfilled) and cohort 2 (filled). (C) Spine density 
for control (C) and schizophrenia (Sz) subjects in pairs in which the Sz subject MAP2-IR 
was above (MAP2-IR Normal) or below (MAP2-IR Low) the minimum MAP2-IR 
observed in control subjects. Bars represent mean values for each group. (D) Spine 
number for control (C) and schizophrenia (Sz) subjects in pairs in which the Sz subject 
MAP2-IR was above (MAP2-IR Normal) or below (MAP2-IR Low) the minimum 
MAP2-IR observed in control subjects. Bars represent mean values for each group.  
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3.3.8 Antipsychotic Exposed Monkeys 
We found no significant effect of chronic haloperidol exposure on MAP2-IR. [Figure 9; primary 
F(1,2.77)=0.54 p=0.52 and secondary F(1,5.76)=0.15 p=0.71 ]. We previously reported no 
significant effect of haloperidol exposure on spine density in this group of animals. (Sweet et al 
2009)  
 
Figure 9. Mean MAP2 intensity is unchanged in haloperidol exposed macaques. 
Chronic antipsychotic exposure did not alter MAP2-IR in adult male macaques. Error 
bars are ± SEM. 
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3.4 DISCUSSION 
We hypothesized MAP2-IR is reduced in BA41 of individuals with Sz. Using quantitative 
fluorescence confocal microscopy, we examined alterations in MAP2-IR intensity in BA41 deep 
layer 3 and examined the relationship between MAP2-IR and dendritic spine markers within the 
same region. We found that MAP2-IR intensity was significantly reduced in Sz subjects in 
comparison to matched control subjects. Dendritic spine density and number were also reduced 
and were associated with MAP2-IR intensity. Twelve (60%) Sz subjects exhibited MAP2-IR 
intensity levels lower than the lowest control value. In this subset, deemed MAP2-IR Low, there 
were significant reductions in spine density and spine number while there were no significant 
reductions in spine density and number in MAP2-IR Normal subjects. Our findings are the first 
to show a change in MAP2-IR within the auditory cortex of individuals with Sz, and to relate 
MAP2-IR to dendritic spine alterations.  
3.4.1 Schizophrenia Associated MAP2-IR Changes 
We found a significant reduction in MAP2-IR in BA 41 deep layer 3. Although the 
immunoreactive intensity and subcellular location of MAP2 are sensitive to the effects of 
increasing PMI (Figure 6), (Schwab et al 1994) it is unlikely that our finding can be attributed to 
the effects of PMI or effects of age, sex, and storage time. Our subject pairs were well matched 
for these variables, mitigating their influence. Moreover, we saw no significant association of 
any of the aforementioned variables with MAP2-IR within our statistical models, and no 
significant interactions between them and diagnosis. Similarly, none of the prior studies of 
MAP2-IR in Sz found significant effects of age, sex, or PMI. (Arnold et al 1991, Jones et al 
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2002, Rioux et al 2004, Rosoklija et al 2005, Somenarain and Jones 2010) Neither we, nor 
Rosoklija et al. (Rosoklija et al 2005) found a significant effect of antipsychotic treatment. 
Finally, we examined whether reduced MAP2-IR results from long term antipsychotic exposure 
in an animal model, and found no effect on MAP2-IR. 
Many previous reports have documented reductions in MAP2-IR in other cortical regions 
linked to Sz pathology.(Arnold et al 1991, Jones et al 2002, Rioux et al 2004, Rosoklija et al 
2005, Somenarain and Jones 2010) The drastic nature of the change in IR lends itself to 
macroscopic observation, which has allowed some groups to qualitatively assess regional IR. 
Within their cohort, Arnold et al.(Arnold et al 1991) found a qualitative loss of MAP2-IR in the 
subiculum and entorhinal cortex of 83% and 66% of their Sz subjects respectively; similar to our 
observation of marked MAP2-IR loss in the auditory cortex in 60% of our Sz subjects. Rosoklija 
et al. (Rosoklija et al 2005) reported qualitatively low or absent MAP2-IR in the subiculum of 
20% of Sz subjects within their cohort but no overall change in IR in comparison to controls 
within the other hippocampal subfields.  In order to quantify this change, others utilized optical 
density measurements  or area fraction analysis.(Jones et al 2002, Somenarain and Jones 2010) 
As measured by Jones et al.(Jones et al 2002), MAP2-IR area fraction was decreased by 45% in 
layer 5 of frontal cortex (BA9) and 40% in layer 3 of BA9, 44% in layer 5 of cingulate cortex 
(BA32), and 32% in layer 3 of BA32 in Sz subjects compared to controls. Somenarain 
(Somenarain and Jones 2010) found a similar result in BA9 area fraction: a 38% reduction in 
layer 5 and a 39% reduction in layer 3.  
Others (Jones et al 2002, Somenarain and Jones 2010) investigated the relationship 
between MAP2-IR reductions and neuron loss finding no differences in cell density in areas that 
showed a disease-specific reduction in MAP2-IR. Similarly, in a previous report,(Dorph-
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Petersen et al 2009) the pyramidal neuron number in the twelve pairs that comprise cohort 1 in 
the present work was determined to be unchanged in BA41 layer 3 (Figure 4).  Arnold et al. 
(Arnold et al 1991) found no neuron loss or accompanying increase in markers of 
neurodegeneration (e.g. gliosis, neurofibrillary tangles) in subjects with a decrease in MAP2-IR, 
while Rosoklija et al.(Rosoklija et al 2005)found no increase in gliosis as assessed by glial 
fibrillary acidic protein IR. It is clear from these data that neuron loss does not account for 
reductions in MAP2-IR. Further, using liquid chromatography-mass spectrometry, we have 
shown that MAP2-IR loss is not a result of MAP2 protein loss (S2.). 
The large number of positive studies, despite the different regions, antibodies, and 
approach to quantification, in conjunction with evidence that reduced MAP2-IR does not result 
from common confounds such as PMI, age, and antipsychotic treatment, together lend 
confidence to the conclusion that reduced MAP2-IR represents a disease-associated alteration 
present across cortical regions in a large proportion of subjects with Sz. This interpretation raises 
important questions: what does the decrease in MAP2-IR indicate in terms of molecular changes 
to MAP2, and what consequences might MAP2-IR loss have for neuronal function in Sz? 
3.4.2 Molecular Changes in MAP2 Leading to MAP2-IR Loss 
MAP2, like its axonal homolog MAP tau, is tightly regulated by a strict balance of 
phosphorylation; extremes in either direction lead to decreased MT binding, nucleation, 
assembly, and stabilization. (Brugg and Matus 1991, Murthy and Flavin 1983, Sanchez et al 
2000, Tsuyama et al 1986) It is important to note, that even at intermediate, endogenous levels of 
phosphate load, site-specific phosphorylation is more important than total phosphate amount in 
regulating MAP2-MT interaction.(Ainsztein and Purich 1994, Brugg and Matus 1991) MAP2 is 
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comprised of four functional domains tasked with different roles: 1) the n-terminal domain, 
which binds the RII subunit of cAMP-dependent protein kinase (PKA) 2) the 1372 amino acid 
(aa) projection domain found only in high molecular weight isoforms of MAP2 (i.e. MAP2A and 
MAP2B) that regulates the spacing of MT bundles (Belanger et al 2002) 3) the regulatory proline 
rich region, and; 4) the microtubule binding domain (MTBD) responsible for binding to MT’s 
and actin. (Sanchez et al 2000) A number of protein kinases and phosphatases interact with sites 
within each region resulting in diverse functional consequences. To illustrate, PKA incorporates 
phosphate groups at sites primarily within the n-terminal and projection domains, thereby 
disrupting MAP2-MT binding and MT nucleation. (Itoh et al 1997) Similarly, Cdc2 kinase, 
which phosphorylates the MTBD, also disrupts MAP2-MT binding and MT nucleation, but 
additionally disrupts MT stabilization.(Itoh et al 1997) Even within functional domains, site-
directed kinases can produce highly specific effects.(Ainsztein and Purich 1994) Although 
MAP2 is a natively unfolded protein, it can adopt complex folded conformations; a process that 
is sensitive to divalent cation concentration and depends on the C-terminal MTBD.(Ainsztein 
and Purich 1994, Di Noto et al 1999, Wille et al 1992) While not firmly established, it has been 
proposed that this process could potentially be a result of the high abundance of proline residues 
within the 156 aa adjacent to the MTBD. (Farah and Leclerc 2008, Sanchez et al 2000) Proline 
has the ability to exist in cis- and trans- isomers based on phosphorylation state and therefore 
may underlie MAP2’s previously observed ability to fold upon itself. (Wille et al 1992) 
Phosphorylation-dependent folding has been previously demonstrated in MAP tau models of 
disease. (Jeganathan et al 2008) Thus, the reduction of MAP2-IR in our Sz subjects could 
indicate disease-associated alterations in MAP2 phosphorylation which, via changes in binding 
to MT targets or in folding, prevents the antibody from reaching its binding site. 
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It should be noted that other possibilities exist to explain MAP2-IR loss. Rather than a 
change in MAP2 protein, the phenomenon could represent a change in the network of proteins 
that bind MAP2. Outside of its role in the cytoskeleton, MAP2 serves as a receptor for the 
neurosteroids pregnenolone (PREG) and dehydroepiandrosterone (DHEA), an interaction which 
impacts dendritic stability, changes MAP2 phosphorylation state, and influences MAP2 
immunostaining. (Fontaine-Lenoir et al 2006, Murakami et al 2000) Recent studies have 
identified changes in serum levels of both of these neurosteroids in patients with first-episode 
psychosis and linked this phenomenon to symptom severity.(Ritsner 2011) MAP2 also serves as 
an anchoring protein linking PKA to class C L-type Ca2+ channels,(Davare et al 1999) a class of 
voltage gated Ca2+ channels that have been linked to Sz by genomic studies.(He et al 2014)  
Genetic studies have also identified genes in the immediate early gene activity-regulated 
cytoskeleton-associated gene, Arc, pathway as linked to schizophrenia(Fromer et al 2014, Purcell 
et al 2014). Arc is locally expressed in the dendritic arbor in response to neuronal activity, and it 
has been demonstrated both in vivo and in vitro that up-regulation of Arc reduces MAP2-IR 
independent of MAP2 protein loss.(Fujimoto et al 2004) Dysregulation of NMDA receptor 
activity also changes the subcellular location of the MT plus end capping protein EB3, causing it 
to bind MAP2 at the MTBD.(Kapitein et al 2011) Disease state could potentially alter any of 
these partners, increasing their MAP2 binding and thus obscuring the antibody epitope. In 
support of such an interpretation, Cotter et al.(Cotter et al 2000) found increased MAP2-IR 
dendritic length in subiculum and hippocampus of subjects with schizophrenia using an antigen 
retrieval method that disrupts non-covalent protein binding (and/or MAP2 folding), potentially 
representing a greater unmasking of MAP2-IR sites in schizophrenia subjects.  
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3.4.3 Potential Consequences of MAP2-IR Loss for Neuronal Function in Schizophrenia  
A primary role of MAP2 is stabilizing mature MT bundles in the dendrite. (Belanger et al 2002, 
Dehmelt and Halpain 2004, Farah and Leclerc 2008, Sanchez et al 2000, Teng et al 2001) Recent 
evidence has elucidated effects of MTs on dendritic spine morphology, finding that dynamic 
MTs enter developing and mature dendritic spines in response to synaptic activity. (Gu et al 
2008, Hu et al 2008, Jaworski et al 2009) This entry leads to a transition from immature 
filopodia to mature mushroom head structure in developing spines. (Hu et al 2008, Jaworski et al 
2009) Similarly, MT entry into spines has been demonstrated to be protective against spine 
reduction induced by long term depression, a process in which MAP2 participates. The link 
between spine structural plasticity and MAP2 is further supported by findings that inhibition of 
MT polymerization leads to a loss of mature spine structure, prevents long-term potentiation, and 
ultimately, ends in a drastic loss of spines themselves.(Gu et al 2008, Hu et al 2008, Jaworski et 
al 2009)  
 
We therefore hypothesized that MAP2-IR reductions would be associated with dendritic 
spine loss in Sz. Our hypothesis was supported by our finding that the reduction in dendritic 
spines in Sz subjects was restricted to those with substantial reductions in MAP2-IR. Our finding 
replicated and extended our prior observation that dendritic spine density is significantly lower in 
deep layer 3 of primary auditory cortex in individuals with Sz. (Sweet et al 2009) The current 
observation was made in a non-overlapping cohort of subjects. Furthermore, by using stereologic 
methods to provide an estimation of spine number, we also showed that the reported loss in spine 
density reflects a loss of spines themselves as opposed to an expansion in surrounding tissue 
volume. This finding parallels Golgi-impregnation studies which have documented a Sz-
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associated loss of layer 3 spine structures per unit of dendrite length in dorsolateral prefrontal 
cortex(Garey et al 1998, Glantz and Lewis 2000) and subiculum.(Rosoklija et al 2000) In 
addition, the loss of dendritic spines, in the absence of a change in neuron number, can be seen 
as congruent with earlier hypotheses of reduced neuropil in schizophrenia(Selemon and 
Goldman-Rakic 1999). In contrast, the reduced detectability of dendrites due to lower MAP2-IR 
precludes any firm conclusion regarding whether reduced dendritic length or arborization is 
present and contributes to reduced neuropil in our subjects. Given its role in maintaining cell 
structure, it is plausible that changes to MAP2 protein may also contribute to reduced somal 
volume, another cellular change previously described in this area of cortex (Sweet et al 2004).  
3.4.4 Summary 
We found that 60% of subjects with Sz had dramatic reductions in MAP2-IR in BA 41, and that 
this deficit was correlated with reduced dendritic spine density. The loss of MAP2-IR was not 
explained by technical factors or subject comorbidities and treatments, suggesting MAP2-IR 
reduction is a disease-associated alteration. Importantly, reduced MAP2-IR was not due to a loss 
of MAP2 protein. Future studies will need to identify whether reduced MAP2-IR in Sz results 
from alterations to MAP2 phosphorylation state, conformation, and/or binding to its interaction 
partners.  This process will be aided by identifying the affected functional domain of MAP2 that 
contributes to IR reduction, and by investigation of disease linked changes in the MAP2 protein 
interactome. Because MAP2 shares substantial sequence, regulatory, and functional homology 
with MAP tau, (Dehmelt and Halpain 2005) the wealth of knowledge tau biology and the rapidly 
expanding field of tau therapeutics(Wischik et al 2014) provide  resources for identifying how 
MAP2 is altered in Sz and possible leads to novel therapeutics.   
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